SOTYKTU

Aug 17, 2026

Summary TYK2 inhibitors are emerging as a major class of oral immunology therapies, aiming to combine biologic-level efficacy with the convenience of a pill and fewer safety concerns than broader JAK inhibitors. Bristol Myers Squibb’s SOTYKTU remains the first approved TYK2 inhibitor and expanded its positio...

Mar 13, 2026

Summary  Bristol Myers Squibb’s SOTYKTU has received FDA approval for adults with active psoriatic arthritis, becoming the first and only TYK2 inhibitor authorized for this indication. The drug extends its reach beyond its 2022 approval for moderate-to-severe plaque psoriasis, reinforcing BMS’s bid to b...